Synpromics
Synthetic promoters to control gene expressions and regulations.
Launch date
Employees
Market cap
-
Enterprise valuation
€23—35m (Dealroom.co estimates Apr 2017.)
Company register number SC384375
Roslin Scotland (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.5m | 1.6m | 1.4m | 2.0m | <1m | 7.0m | 10.5m |
| % growth | 1058 % | 4 % | (7 %) | 40 % | (94 %) | 5839 % | 51 % |
| EBITDA | (<1m) | (1.8m) | (2.1m) | (2.0m) | (3.8m) | 1.4m | 2.9m |
| % EBITDA margin | (31 %) | (116 %) | (147 %) | (98 %) | (3194 %) | 20 % | 28 % |
| Profit | (<1m) | (2.0m) | (1.6m) | (2.1m) | (5.7m) | 1.0m | 5.3m |
| % profit margin | (35 %) | (129 %) | (109 %) | (103 %) | (4879 %) | 14 % | 50 % |
| R&D budget | 2.0m | 2.0m | 2.0m | 3.0m | - | - | - |
| R&D % of revenue | 134 % | 129 % | 139 % | 149 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | Seed | |
| N/A | N/A | Grant | |
N/A | Early VC | ||
£2.1m | Early VC | ||
* | €5.8m | Early VC | |
£1.9m | Grant | ||
* | N/A | Acquisition | |
| Total Funding | €10.6m | ||
Related Content
Recent News about Synpromics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.